VERAXA Biotech (NASDAQ: VRXA) announced on July 2, 2026, that it has initiated cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. The partnership will leverage ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development. This move follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This approach addresses a critical challenge in cancer immunotherapy: minimizing damage to healthy tissues while maximizing the immune system's attack on tumors.
The implications of this development are significant for patients and the oncology field. If successful, VERAXA's BiTAC platform could offer a safer and more effective treatment option for cancers that are currently difficult to treat with existing T-cell engagers. The ability to dose higher without severe side effects could improve outcomes and quality of life for patients. For the industry, the platform represents a potential shift toward more precise immunotherapies that reduce systemic toxicity, a major hurdle in the development of bispecific antibodies. The collaboration with ATUM also underscores the importance of robust cell line development in bringing such complex biologics to market efficiently.
VERAXA Biotech is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution. The BiTAC(R) trademark is registered to VERAXA Biotech GmbH. For the latest news and updates relating to VRXA, visit the company's newsroom at https://ibn.fm/VRXA. The full press release is available at https://ibn.fm/FCIlk.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These are detailed in the company's filings with the SEC. Investors should not place undue reliance on such statements.
